A novel cell tool for α2δ-1-NMDAR target-based analgesic drug discovery.
- Author:
Lin DONG
1
;
Yiya ZHANG
2
;
Jinjun CHEN
1
Author Information
- Publication Type:Journal Article
- Keywords: NMDA receptor; neuropathic pain; target-based drug discover; α2δ-1; α2δ-1-NMDAR complex
- MeSH: Analgesics/therapeutic use*; Animals; Drug Discovery; HEK293 Cells; Humans; Neuralgia/metabolism*; Receptors, N-Methyl-D-Aspartate/genetics*
- From: Chinese Journal of Biotechnology 2022;38(3):1149-1158
- CountryChina
- Language:Chinese
- Abstract: The α2δ-1 protein coded by Cacna2d1 is dramatically up-regulated in dorsal root ganglion (DRG) neurons and spinal dorsal horn following sensory nerve injury in various animal models of neuropathic pain. Cacna2d1 overexpression potentiates presynaptic and postsynaptic NMDAR activity of spinal dorsal horn neurons to cause pain hypersensitivity. The α2δ-1-NMDAR interaction promotes surface trafficking and synaptic targeting of NMDARs in neuropathic pain caused by chemotherapeutic agents and peripheral nerve injury, as well as in other pathological conditions such as in the paraventricular nucleus (PVN) with neurogenic hypertension and in the brain with ischemic stroke. The lentiviral transfection method was used to construct a human embryonic kidney HEK293T cell line that could stably express α2δ-1-NMDAR complex. A stably transfected cell line was observed by florescence microscope, and identified by RT-qPCR and Western blotting. The results showed that the HEK293T cell line was successfully transfected and the genes could be stably expressed. Subsequently, the transfected cell line was successfully developed into a target drug screening system using patch clamp techniques. It provides a promising cell model for further research on the interaction mechanism of α2δ-1-NMDAR complex and drug screening for chronic pain and related diseases with low side effects.
